Current diagnosis and management of adenomyosis in Canada: A survey of Canadian gynaecologists

Objective: The purpose of this study was to understand how Canadian Obstetricians/Gynaecologists (OBGYNs) diagnose and manage adenomyosis. Methods: This cross-sectional performed via an online survey distributed 262 OBGYNs at three universities (University Toronto, University Calgary, McMaster University). Results: A total 137 responses were obtained out (52.3%) with a completion rate 98%. Adenomyosis diagnosis in 6%–10% patients seen by OBGYNs. most common clinical symptoms included heavy menstrual bleeding (HMB) (82.8%) dysmenorrhea (91.0%). Most participants (83%) used transvaginal ultrasound (TVUS) as first-line imaging for Many respondents (35.8%) indicated that adenomyosis not associated infertility or recurrent miscarriage. Treatment considerations all levonorgestrel intra-uterine system (LNG-IUS) (91.8%), hysterectomy (88.8%), expectant management (85.1%), combined hormonal contraceptives (CHC) (83.6%), tranexamic acid (81.3%), gonadotropin releasing hormone (GnRH) agonists (64.2%), depo-provera dienogest (57.5%), norethisterone acetate (NETA) (40.3%). Treatments wishing conceive (79.1%), CHC (44.8%), LNG-IUS (32.8%), GnRH (35.8%). Excision would only be offered 24% respondents. Uterine artery embolization (UAE) the treatment 44% Finally, 82.8% use improvement follow success. Conclusion: Practice varies across Canada despite recent emerging evidence adenomyosis, highlighting need practice guideline on